Rafivirumab, formerly known as CR57, embodies a promising agent targeting VEGF receptor 2 and VEGFR2. Its path from preclinical identification involved a substantial commitment by Curis , succeeded by acquisition with BMS . The therapeutic assessment has included multiple trial evaluations , larg